Oral Bioavailability Assessment

AYMAN F. EL-KATTAN, B. Pharm, PhD, is Associate Research Fellow in Pfizer's Pharmacokinetics, Dynamics, and Metabolism Department, Cambridge Laboratories and an Adjunct Professor at College of Pharmacy-University of Rhode Island in Rhode Island, US. Dr. El-Kattan is a reviewer for several journals and is an active member of the American Association of Pharmaceutical Scientists (AAPS). He serves on the executive committee of the Drug Transporter focus group. He has been invited speaker 50 times at national/international conferences and has published over 100 papers in peer-reviewed Journals, book chapters, and proceedings.

• 1 Drug Pharmacokinetics and Toxicokinetics 12 GIT Anatomy and Physiology and Drug Oral Bioavailability: Impact of Species Differences 353 Drug Routes of Excretion 774 Physicochemical and Biopharmaceutical Properties that Affect Drug Absorption of Compounds Absorbed by Passive Diffusion 1395 Physicochemical and Biopharmaceutical Factors Affecting Hepatic/Intestinal First-Pass Effect 1736 Impact of Intestinal Efflux Transporters on Oral Absorption 2037 Impact of Influx Transporters on Drug Absorption 2698 Extended Clearance Classification System (ECCS) and its Utility in Predicting Clearance Rate-Determining Step in Drug Discovery 3099 In Vitro and In Situ Approaches to Measure Intestinal Permeability and Efflux Transporters 33110 In Silico Approaches to Predict Intestinal Permeability 34711 In Vivo Preclinical Approaches to Deconvolute The Contribution of First-Pass Effect from Oral Absorption 35712 In Vitro Approaches to Assess Hepatic Metabolism and First-Pass Effect 37713 The Utility of ECCS as a Roadmap to Improve Oral Bioavailability of New Molecular Entities: Industrial Perspective 387Index 431